论文部分内容阅读
多发性骨髓瘤（ｍｕｌｔｉｐｌｅｍｙｅｌｏｍａＭＭ）是克隆性浆细胞恶性增殖性疾病，应用马法兰－强的松标准化疗或联合烷化剂治疗，中位生存时间３年。近１０年来大剂量马法兰加（或不加）全身照射，辅以骨髓或外周血干细胞支持，并联用造血细胞生长因子，预后有一定改善，?
Multiplemyeloma (MM) is a malignant proliferative disorder of clonal plasma cells. It is treated with Mafari-prednisone standard chemotherapy or combined with alkylating agents. The median survival time is 3 years. In the past 10 years, large-dose Maflanca (or none) whole-body irradiation, supplemented with bone marrow or peripheral blood stem cell support, combined with hematopoietic cell growth factors, has shown some improvement in prognosis.